Day: December 8, 2019

Oral presentations on data from two clinical trials in chronic lymphocytic leukemia or small lymphocytic lymphomaPoster presentation on data from clinical trial of BRUKINSA combined with tislelizumab in B-cell malignanciesCAMBRIDGE, Mass. and BEIJING, China, Dec. 08, 2019 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced clinical data from three trials of its BTK inhibitor BRUKINSA™ (zanubrutinib) were presented at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, FL. In two oral presentations of BRUKINSA in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the drug candidate...

~ Sustained FIX Activity at Therapeutic Levels1 Up to 50% of Normal at One Year After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~~ Zero Bleeds and No Requirement for Immunosuppression in One Year Following Dosing with Etranacogene Dezaparvovec ~~ Long-term Clinical Benefit and Tolerability of AMT-060 Maintained in All Patients Through up to 4 Years of Follow-Up ~~ Investor Webcast on Monday, December 9, 2019 at 7:00 a.m. EST ~LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 08, 2019 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated clinical data on the three patients treated in uniQure’s ongoing Phase IIb study of etranacogene dezaparvovec, an investigational AAV5-based gene therapy...

MONTRÉAL, Dec. 08, 2019 (GLOBE NEWSWIRE) — Alliance Forêt Boréale, Ville de Dolbeau-Mistassini, Hebdos Québec, Métro Média as well as unions representing employees of TC Transcontinental (TSX: TCL.A TCL.B), namely the Centrale des syndicats démocratiques (CSD), the Syndicat des travailleurs industriels et commerciaux (STIC) and the Syndicat des Teamsters, are standing together with TC Transcontinental to avoid the disappearance of Publisac and the collapse of the socioeconomic system that relies on it.They invite media representatives to a press conference on Monday, December 9, 2019, at 11 a.m. at Centre Mont-Royal, 2200 Mansfield Street, Montréal. The press conference will be held in French.DATEBOOKPlease confirm your attendance with Viviane Ross of NATIONAL at (514) 827-4250 or at vross@national.ca.             About TC TranscontinentalTC Transcontinental...

MONTRÉAL, 08 déc. 2019 (GLOBE NEWSWIRE) — Alliance Forêt Boréale, la Ville de Dolbeau-Mistassini, Hebdos Québec, Métro Média ainsi que des syndicats représentant des employés de TC Transcontinental (TSX : TCL.A TCL.B), soit la Centrale des syndicats démocratiques (CSD), le Syndicat des travailleurs industriels et commerciaux (STIC) et le Syndicat des Teamsters se mobilisent aux côtés de TC Transcontinental pour éviter la disparition du Publisac et l’écroulement du système socio-économique qui en dépend.Ils invitent les représentants des médias à une conférence de presse qui se tiendra le lundi 9 décembre 2019 à 11 h, au Centre Mont-Royal, situé au 2200, rue Mansfield à Montréal.AIDE-MÉMOIREPrière de confirmer votre présence auprès de Viviane Ross de NATIONAL au (514) 827-4250 ou à vross@national.ca.                 À propos de TC TranscontinentalTC...

– Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma –– Enhanced activity (40% CR rate, 70% ORR) observed in AITL patients with KIR mutations, a CXCL pathway-associated biomarker –– Company to conduct a single-arm, Phase 2 registration-directed trial of tipifarnib in AITL following positive feedback from FDA –– Trial could support an NDA seeking accelerated approval for tipifarnib monotherapy in AITL and/or AITL with KIR mutations –ORLANDO and SAN DIEGO, Dec. 08, 2019 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced clinical and regulatory updates for its lead drug candidate, tipifarnib, in angioimmunoblastic T-cell...

FT596 as a Monotherapy Demonstrates Comparable Anti-tumor Activity to CAR19 T Cells In Vivo in Humanized Mouse Model of LymphomaCombination of FT596 with Rituximab Shows Durable Tumor Clearance In Vivo in Preclinical Lymphoma ModelCompany Plans to Initiate Enrollment of First-in-human Clinical Trial of FT596 in Early 2020SAN DIEGO, Dec. 08, 2019 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced new in vivo preclinical data for FT596, its off-the-shelf, multi-antigen targeting natural killer (NK) cell product candidate derived from a clonal master engineered induced pluripotent stem cell (iPSC) line. The data were featured during the 61st American Society of Hematology...

Company Announcement No. 17Aalborg, 8. December 2019Seluxit signs an agreement with a new client within in the healthcare industrySeluxit is pleased to announce an upcoming collaboration with a Danish company within the healthcare industry, which currently wishes to remain anonymous. The collaboration will enable IoT Fleet Management of current medical devices.  Seluxit will develop the solution using its standard hardware and software components and the Seluxit cloud based IoT platform.CEO, Daniel Lux: “We are very pleased to enter into this cooperation with a new partner in Denmark, using our core technology and standard components. IoT technology has a huge potential to improve our lives with smarter solutions to existing great products.”For further information, please contact CEO Daniel Lux.You can subscribe to our investor newsletter...

Selskabsmeddelelse nr. 17Aalborg, 8. december 2019 Seluxit indgår en aftale med en kunde indenfor sundhedssektoren.Seluxit glæder sig over at kunne offentliggøre et kommende samarbejde med et dansk firma inden for sundhedssektoren, som i øjeblikket ønsker at være anonym. Der er tale om en IoT baseret Fleet Management og overvågnings løsning til medicinsk udstyr. Seluxit udvikler løsningen ved hjælp af sine standard hardware og software moduler samt Seluxit’s egen cloud-baseret IoT-platform.”Vi er meget glade for at indgå dette samarbejde med en ny partner i Danmark, og kunne bruge vores kerneteknologi og standardkomponenter. IoT-teknologi har et enormt potentiale til at forbedre vores liv med smartere løsninger for eksisterende kvalitetsprodukter”For yderligere oplysninger kontakt CEO Daniel Lux.Du kan også abonnere på vores investornyhedsbrev...

– Membrane bound IL-15 (mbIL15) improves anti-tumor effect of TCR-modified T cells –– T cells expressing T-cell receptor (TCR) and mbIL15 can be infused day after gene transfer –BOSTON, Dec. 08, 2019 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq:ZIOP), today announced the presentation of pre-clinical data of Rapid Personalized Manufacture (RPM), in the “Adoptive Immunotherapy: Mechanisms and New Approaches” session at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando.“These pre-clinical data demonstrate that T cells genetically modified using DNA plasmids from the Sleeping Beauty system to express TCR with membrane bound IL-15 (mbIL15) exhibit anti-tumor effects,” said Drew Deniger, Ph.D., leader of Ziopharm’s TCR program. “These data build on our approach to reduce the cost...

100% overall response rate (ORR) in relapsed/refractory CLL patients treated with U2 (umbralisib + ublituximab) plus venetoclax at cycle 7 (n=13)100% of patients (n=9) achieved undetectable MRD in the peripheral blood after 12 months of therapy and 78% achieved undetectable MRD in bone marrow and have stopped all therapyNo patients have progressed to dateInvestor and analyst event to be held on Monday, December 9, 2019 at 7:30 PM ET at the Hyatt Regency Orlando featuring a fireside chat with leading clinical investigatorsNEW YORK, Dec. 08, 2019 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced triple therapy data from the Phase I/II study of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in combination with umbralisib (TGR-1202), the Company’s oral, dual inhibitor...